Freedland SJ - Search Results

1

Prostate Specific Antigen Density as a Predictor of Clinically Significant Prostate Cancer When the Prostate Specific Antigen is in the Diagnostic Gray Zone: Defining the Optimum Cutoff Point Stratified by Race and Body Mass Index.

Aminsharifi A, Howard L, Wu Y, De Hoedt A, Bailey C, Freedland SJ, Polascik TJ. Aminsharifi A, et al. Among authors: freedland sj. J Urol. 2018 Oct;200(4):758-766. doi: 10.1016/j.juro.2018.05.016. Epub 2018 Jul 6. J Urol. 2018. PMID: 29758219

2

Clinical characteristics in black and white men with prostate cancer in an equal access medical center.

Freedland SJ, Sutter ME, Naitoh J, Dorey F, Csathy GS, Aronson WJ. Freedland SJ, et al. Urology. 2000 Mar;55(3):387-90. doi: 10.1016/s0090-4295(99)00461-6. Urology. 2000. PMID: 10699616

3

Race is not an independent predictor of biochemical recurrence after radical prostatectomy in an equal access medical center.

Freedland SJ, Jalkut M, Dorey F, Sutter ME, Aronson WJ. Freedland SJ, et al. Urology. 2000 Jul;56(1):87-91. doi: 10.1016/s0090-4295(00)00587-2. Urology. 2000. PMID: 10869631

4

Multivariate analysis of race and adverse pathologic findings after radical prostatectomy.

Freedland SJ, Dorey F, Aronson WJ. Freedland SJ, et al. Urology. 2000 Nov 1;56(5):807-11. doi: 10.1016/s0090-4295(00)00754-8. Urology. 2000. PMID: 11068307

5

Preoperative PSA velocity and doubling time do not predict adverse pathologic features or biochemical recurrence after radical prostatectomy.

Freedland SJ, Dorey F, Aronson WJ. Freedland SJ, et al. Urology. 2001 Mar;57(3):476-80. doi: 10.1016/s0090-4295(00)01016-5. Urology. 2001. PMID: 11248623

6

Polyarteritis nodosa presenting as hematuria and a testicular mass.

Eilber KS, Freedland SJ, Rajfer J. Eilber KS, et al. Among authors: freedland sj. J Urol. 2001 Aug;166(2):624. J Urol. 2001. PMID: 11458092 No abstract available.

7

Percent prostate needle biopsy tissue with cancer is more predictive of biochemical failure or adverse pathology after radical prostatectomy than prostate specific antigen or Gleason score.

Freedland SJ, Csathy GS, Dorey F, Aronson WJ. Freedland SJ, et al. J Urol. 2002 Feb;167(2 Pt 1):516-20. doi: 10.1016/S0022-5347(01)69076-1. J Urol. 2002. PMID: 11792909

8

Effect of ketorolac on renal function after donor nephrectomy.

Freedland SJ, Blanco-Yarosh M, Sun JC, Hale SJ, Elashoff DA, Rajfer J, Gritsch HA. Freedland SJ, et al. Urology. 2002 Jun;59(6):826-30. doi: 10.1016/s0090-4295(02)01514-5. Urology. 2002. PMID: 12031361

9

Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.

Freedland SJ, Wieder JA, Jack GS, Dorey F, deKernion JB, Aronson WJ. Freedland SJ, et al. J Urol. 2002 Jul;168(1):110-5. J Urol. 2002. PMID: 12050502

10

Immunotherapy of prostate cancer.

Freedland SJ, Pantuck AJ, Weider J, Zisman A, Belldegrun AS. Freedland SJ, et al. Curr Urol Rep. 2001 Jun;2(3):242-7. doi: 10.1007/s11934-001-0086-9. Curr Urol Rep. 2001. PMID: 12084272 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

780 results

Search Page

Filters